Vitamin D3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances?

Linda Rolf; Anne Hilde Muris; Ruud Theunissen; Raymond Hupperts; Jan Damoiseaux; Joost Smolders

doi:10.1016/j.jneuroim.2017.11.007

Vitamin D₃ supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances?

Linda Rolf, Anne Hilde Muris, Ruud Theunissen, Raymond Hupperts, Jan Damoiseaux, Joost Smolders^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

11 Citations (Scopus)

Abstract

Vitamin D₃ upregulates IL-2 receptor alpha (IL2RA, CD25)-expression on CD4⁺ T cells in vitro. We investigated effects of 48-weeks vitamin D₃ supplements on CD25-expression by CD4⁺ T cells of patients with multiple sclerosis (MS). There was no significant difference between the vitamin D₃ (n = 30) and placebo group (n = 23) in IL2RA mRNA-expression by PBMC. Likewise, CD25 cell surface-expression by conventional or regulatory T cells (Treg) did not differ between groups, although Treg CD25-expression and circulating soluble-CD25 levels decreased significantly in the placebo but not vitamin D₃-group. We speculate that vitamin D₃ may promote the maintenance of CD25-related immune homeostasis in MS.

Original language	English
Pages (from-to)	50-57
Number of pages	8
Journal	Journal of Neuroimmunology
Volume	314
Early online date	10 Nov 2017
DOIs	https://doi.org/10.1016/j.jneuroim.2017.11.007
Publication status	Published - 15 Jan 2018
Externally published	Yes

Bibliographical note

Funding Information:
The SOLARIUM study was supported by Merck Serono S.A and Nationaal MS Fonds Nederland. We are grateful to the patients for their participation. Also, we thank Nancy Hendrikx (Maastricht University Medical Center, Maastricht, The Netherlands), and dr. S. Frequin (St. Antonius Hospital, Nieuwegein, the Netherlands), drs. F. Verheul (Groene Hart Hospital, Gouda, the Netherlands), drs. J. Samijn (Maasstad Hospital, Rotterdam, the Netherlands) and the MS nurses of the participating centers for their contributions to the study.

Publisher Copyright:
© 2017 Elsevier B.V.

Access to Document

10.1016/j.jneuroim.2017.11.007

Cite this

@article{bd9aee31a4c84f9c9d7e3d66861491c0,

title = "Vitamin D3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances?",

abstract = "Vitamin D3 upregulates IL-2 receptor alpha (IL2RA, CD25)-expression on CD4+ T cells in vitro. We investigated effects of 48-weeks vitamin D3 supplements on CD25-expression by CD4+ T cells of patients with multiple sclerosis (MS). There was no significant difference between the vitamin D3 (n = 30) and placebo group (n = 23) in IL2RA mRNA-expression by PBMC. Likewise, CD25 cell surface-expression by conventional or regulatory T cells (Treg) did not differ between groups, although Treg CD25-expression and circulating soluble-CD25 levels decreased significantly in the placebo but not vitamin D3-group. We speculate that vitamin D3 may promote the maintenance of CD25-related immune homeostasis in MS.",

author = "Linda Rolf and Muris, {Anne Hilde} and Ruud Theunissen and Raymond Hupperts and Jan Damoiseaux and Joost Smolders",

note = "Funding Information: The SOLARIUM study was supported by Merck Serono S.A and Nationaal MS Fonds Nederland. We are grateful to the patients for their participation. Also, we thank Nancy Hendrikx (Maastricht University Medical Center, Maastricht, The Netherlands), and dr. S. Frequin (St. Antonius Hospital, Nieuwegein, the Netherlands), drs. F. Verheul (Groene Hart Hospital, Gouda, the Netherlands), drs. J. Samijn (Maasstad Hospital, Rotterdam, the Netherlands) and the MS nurses of the participating centers for their contributions to the study. Publisher Copyright: {\textcopyright} 2017 Elsevier B.V.",

year = "2018",

month = jan,

day = "15",

doi = "10.1016/j.jneuroim.2017.11.007",

language = "English",

volume = "314",

pages = "50--57",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

}

TY - JOUR

T1 - Vitamin D3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis

T2 - Attenuation of progressive disturbances?

AU - Rolf, Linda

AU - Muris, Anne Hilde

AU - Theunissen, Ruud

AU - Hupperts, Raymond

AU - Damoiseaux, Jan

AU - Smolders, Joost

N1 - Funding Information: The SOLARIUM study was supported by Merck Serono S.A and Nationaal MS Fonds Nederland. We are grateful to the patients for their participation. Also, we thank Nancy Hendrikx (Maastricht University Medical Center, Maastricht, The Netherlands), and dr. S. Frequin (St. Antonius Hospital, Nieuwegein, the Netherlands), drs. F. Verheul (Groene Hart Hospital, Gouda, the Netherlands), drs. J. Samijn (Maasstad Hospital, Rotterdam, the Netherlands) and the MS nurses of the participating centers for their contributions to the study. Publisher Copyright: © 2017 Elsevier B.V.

PY - 2018/1/15

Y1 - 2018/1/15

N2 - Vitamin D3 upregulates IL-2 receptor alpha (IL2RA, CD25)-expression on CD4+ T cells in vitro. We investigated effects of 48-weeks vitamin D3 supplements on CD25-expression by CD4+ T cells of patients with multiple sclerosis (MS). There was no significant difference between the vitamin D3 (n = 30) and placebo group (n = 23) in IL2RA mRNA-expression by PBMC. Likewise, CD25 cell surface-expression by conventional or regulatory T cells (Treg) did not differ between groups, although Treg CD25-expression and circulating soluble-CD25 levels decreased significantly in the placebo but not vitamin D3-group. We speculate that vitamin D3 may promote the maintenance of CD25-related immune homeostasis in MS.

AB - Vitamin D3 upregulates IL-2 receptor alpha (IL2RA, CD25)-expression on CD4+ T cells in vitro. We investigated effects of 48-weeks vitamin D3 supplements on CD25-expression by CD4+ T cells of patients with multiple sclerosis (MS). There was no significant difference between the vitamin D3 (n = 30) and placebo group (n = 23) in IL2RA mRNA-expression by PBMC. Likewise, CD25 cell surface-expression by conventional or regulatory T cells (Treg) did not differ between groups, although Treg CD25-expression and circulating soluble-CD25 levels decreased significantly in the placebo but not vitamin D3-group. We speculate that vitamin D3 may promote the maintenance of CD25-related immune homeostasis in MS.

UR - http://www.scopus.com/inward/record.url?scp=85034455805&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2017.11.007

DO - 10.1016/j.jneuroim.2017.11.007

M3 - Article

C2 - 29153546

AN - SCOPUS:85034455805

SN - 0165-5728

VL - 314

SP - 50

EP - 57

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

ER -

Vitamin D₃ supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances?

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this